Esreboxetine

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H319871

CAS#: 98819-76-2

Description: Esreboxetine, also known as PNU-165442 and (S,S)-Reboxetine, is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued. It is the (+)-(S,S)-enantiomer of reboxetine and is even more selective in comparison. However, recently it has been shown that esreboxetine could be effective in fibromyalgia patients.

Chemical Structure

img
Esreboxetine
CAS# 98819-76-2
Instruction

Theoretical Analysis

Hodoodo Cat#: H319871
Name: Esreboxetine
CAS#: 98819-76-2
Chemical Formula: C19H23NO3
Exact Mass: 313.17
Molecular Weight: 313.397
Elemental Analysis: C, 72.82; H, 7.40; N, 4.47; O, 15.32

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: PNU-165442; PNU 165442; PNU165442; (S,S)-Reboxetine; Esreboxetine

IUPAC/Chemical Name: (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)morpholine

InChi Key: CBQGYUDMJHNJBX-OALUTQOASA-N

InChi Code: InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1

SMILES Code: CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 313.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fujimori I, Yukawa T, Kamei T, Nakada Y, Sakauchi N, Yamada M, Ohba Y,
Takiguchi M, Kuno M, Kamo I, Nakagawa H, Hamada T, Igari T, Okuda T, Yamamoto S,
Tsukamoto T, Ishichi Y, Ueno H. Design, synthesis and biological evaluation of a
novel series of peripheral-selective noradrenaline reuptake inhibitor. Bioorg Med
Chem. 2015 Aug 1;23(15):5000-14. doi: 10.1016/j.bmc.2015.05.017. Epub 2015 May
15. PubMed PMID: 26051602.


2: Shen F, Tsuruda PR, Smith JA, Obedencio GP, Martin WJ. Relative contributions
of norepinephrine and serotonin transporters to antinociceptive synergy between
monoamine reuptake inhibitors and morphine in the rat formalin model. PLoS One.
2013 Sep 30;8(9):e74891. doi: 10.1371/journal.pone.0074891. eCollection 2013.
PubMed PMID: 24098676; PubMed Central PMCID: PMC3787017.


3: Arnold LM, Hirsch I, Sanders P, Ellis A, Hughes B. Safety and efficacy of
esreboxetine in patients with fibromyalgia: a fourteen-week, randomized,
double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum.
2012 Jul;64(7):2387-97. doi: 10.1002/art.34390. PubMed PMID: 22275142.


4: Arnold LM, Chatamra K, Hirsch I, Stoker M. Safety and efficacy of esreboxetine
in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind,
placebo-controlled study. Clin Ther. 2010 Aug;32(9):1618-32. doi:
10.1016/j.clinthera.2010.08.003. PubMed PMID: 20974319.


5: Klarskov N, Scholfield D, Soma K, Darekar A, Mills I, Lose G. Measurement of
urethral closure function in women with stress urinary incontinence. J Urol. 2009
Jun;181(6):2628-33; discussion 2633. doi: 10.1016/j.juro.2009.01.114. Epub 2009
Apr 16. PubMed PMID: 19375093.